NPS 846

Drug Profile

NPS 846

Latest Information Update: 06 Jan 2000

Price : $50

At a glance

  • Originator NPS Pharmaceuticals
  • Class Analgesics; Fluorobenzenes; Neuroprotectants; Propylamines
  • Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders; Pain

Most Recent Events

  • 06 Jan 2000 Discontinued-Preclinical for Neurological disorders in USA (Unknown route)
  • 06 Jan 2000 Discontinued-Preclinical for Pain in USA (Unknown route)
  • 09 Jun 1997 Preclinical development for Neurological disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top